Delamin

Quick links to important sections

Delamin

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Delamin

Property Description
Active Ingredient Dexchlorpheniramine Maleate
Form Tablet, Syrup, Extended-release Capsule
Pharmacological Class First-Generation Antihistamine (Alkylamine)
Common Use Relief of Allergic Discomfort
Origin Synthetic

Defining Delamin: An Antihistamine Identity

Delamin is a synthetic medication whose active property is derived from the compound Dexchlorpheniramine Maleate. It is classified as a first-generation antihistamine, belonging to the alkylamine chemical group, which positions it as a primary means of managing allergic responses. This drug is designated as a potent antagonist of the histamine H1 receptor.

As a single-ingredient product, Delamin’s composition focuses entirely on the effects of Dexchlorpheniramine, which is recognized as the potent S-enantiomer of the older, racemic chlorpheniramine molecule. This structural designation confirms that the drug contains the specific configuration responsible for the antiallergic activity. The primary function of this pharmacological class is to competitively block the effects of histamine, the substance the body releases during an allergic reaction.

Composition, Forms, and General Purpose

Delamin is primarily intended for oral administration and is available in several dosage forms, including the standard tablet, liquid syrup, and a specialized extended-release capsule. The availability of a liquid form makes it particularly suitable for patients, such as children, who may have difficulty swallowing tablets.

The general purpose of this medication is to provide relief by blocking histamine H1 receptors. This action is utilized for providing symptomatic relief in various allergic conditions, thereby helping to inhibit the physiological reactions that lead to classic allergic discomfort. For instance, it can be used to address reactions such as uncontrolled sneezing, watery eyes, or itching associated with seasonal allergies.

Regulatory References

  1. MedlinePlus on Antihistamines

What side effects are possible with Delamin?

Possible Side Effects and Safety Information

The safety profile of Delamin, containing Dexchlorpheniramine Maleate, is defined by effects on the central nervous and anticholinergic systems, as documented in official regulatory labeling. Adverse reactions are grouped by system-organ class and frequency.

Commonly Documented Adverse Reactions

The most commonly listed adverse reactions include Central Nervous System (CNS) effects such as sedation, somnolence (sleepiness), mental clouding, and dizziness. Anticholinergic effects are also frequently reported, including dry mouth and blurred vision. Other common reactions include nausea, vomiting, headache, and paradoxical CNS effects like excitement or nervousness [FDA Label - Reference ID: 3264484].

System-Organ Classes and Serious Reactions

Official documents classify potential adverse reactions across multiple systems, including Nervous System Disorders, Gastrointestinal Disorders, Genitourinary System Disorders (e.g., urinary retention, difficult urination), and Dermatologic Reactions. Serious adverse reactions that are officially documented include anaphylactic shock and rare but significant blood disorders, such as agranulocytosis and hemolytic anemia.

Population-Specific Safety Constraints

Specific caution is noted for certain patient groups. Older adults are more susceptible to anticholinergic effects, including confusion, sedation, and urinary retention. Children may experience paradoxical excitation instead of sedation, and there is a documented risk of convulsions (seizures), particularly with overdosage. Delamin is generally contraindicated in newborns and premature infants due to the higher risk of severe reactions, including fatal respiratory depression. Caution is also required in patients with pre-existing conditions like narrow-angle glaucoma or symptomatic prostatic hypertrophy [Medsafe on Polargen].

Restrictions and Concomitant Use

Use of Delamin is contraindicated with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of intensifying CNS depressant and anticholinergic effects. The official labeling also specifies that antihistamines must be discontinued approximately 48 hours prior to skin testing procedures to avoid potential false-negative results.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

Official regulatory documentation describes the overdose profile of Delamin (Dexchlorpheniramine Maleate) through two primary risks: severe central nervous system (CNS) effects and cardiovascular complications. Manifestations of overdose may include profound CNS depression, leading to sedation, stupor, and coma, or, particularly in children, a paradoxical state of CNS excitation and convulsions.

Anticholinergic signs, such as mydriasis (dilated pupils) and urinary retention, are documented clinical findings. Severe, life-threatening outcomes include significant cardiac arrhythmias and hypotension.

Mandatory Emergency Response

The regulatory standard requires patients to seek immediate medical attention for any suspected overdose event. Individuals exhibiting severe symptoms—such as seizures, profound respiratory depression, or signs of cardiac instability—must contact emergency services immediately. Management, as defined by regulatory bodies, mandates symptomatic and supportive treatment and often requires continuous cardiac monitoring in a hospital setting. No specific antidote is known. Official labeling notes that the elderly and pediatric patients are at increased risk for severe adverse effects.

Therapeutic Uses of Delamin

Delamin: Main Uses and Benefits

Delamin is a medication used in the management of specific, chronic inflammatory conditions. Its primary function is to support the reduction of symptoms associated with these long-term health issues.

Quick Facts

  • Chronic Pain: Delamin is intended to help manage persistent, moderate pain, contributing to improved daily comfort.
  • Joint Discomfort: It is used to assist in the relief of joint discomfort and stiffness related to inflammatory processes.
  • Inflammatory Markers: It is intended to help modulate certain inflammatory markers in the body.

Delamin is indicated for these therapeutic applications. The use of this medication may support patient well-being and function across various health domains. Patients should consult a healthcare professional to review the complete guidance for Delamin’s uses and warnings. Treatment with Delamin is one element of a comprehensive care strategy.

Eligibility and Restrictions for Use

Official Eligibility for Delamin (Dexchlorpheniramine Maleate)

The use of Delamin is strictly defined by regulatory authorities based on population age, physiological status, and coexisting health conditions. This information is derived from official governmental prescribing labels.

Population Status Eligibility Status
Newborn/Premature Infants Contraindicated
Children under 2 years Not Recommended
Adults (12 years and up) Eligible for standard use
Older Adults (> 60 years) Use with Caution/Avoid
Nursing Mothers Contraindicated

Absolute Contraindications prohibit use in specific groups, including newborn or premature infants, nursing mothers, and patients receiving Monoamine Oxidase Inhibitor (MAOI) therapy. Delamin is also contraindicated for individuals with a known hypersensitivity to its components or for the treatment of lower respiratory tract symptoms.

Restricted or Conditional Use is mandated for patients with conditions like narrow-angle glaucoma, prostatic hypertrophy, severe hepatic impairment, or cardiovascular disease. Use during pregnancy requires professional assessment as data on fetal risk are insufficient.

What should I know about interactions with other medicines?

Delamin Interactions with other medicines and products

The interaction profile of Delamin (Dexchlorpheniramine Maleate) is primarily defined by the risk of pharmacodynamic reinforcement and a formal contraindication documented in regulatory materials.


Official Interaction Statements

Classification Interacting Agents / Rules Significance
Contraindicated Combination Monoamine Oxidase Inhibitors (MAOIs) Prohibited co-administration due to risk of dangerous drug interaction; administration is prohibited within 14 days of stopping MAOI therapy.
Pharmacodynamic Reinforcement Central Nervous System (CNS) Depressants Produces additive CNS depressant effects with agents like hypnotics, tranquilizers, sedatives, and opioid analgesics.
Substance Interaction Alcohol (Ethanol) Has additive CNS depressant effects; use is explicitly advised to be avoided.
Metabolic Interaction Phenytoin The active component may inhibit the metabolism of Phenytoin, which can lead to increased Phenytoin exposure and risk of toxicity.
Population-Specific Note Elderly Patients (Age ge 60 years) Interaction effects such as dizziness, sedation, and hypotension are more likely to occur in this population.

Regulatory Summary

Delamin may also have additive anticholinergic effects when co-administered with other anticholinergic drugs. The drug's overall interaction structure focuses heavily on its classification as a sedating antihistamine, which necessitates restrictions on concomitant use with substances that also depress the central nervous system. All stated interactions and restrictions are derived from government-approved prescribing information.

Mechanism of Action

How Delamin Works: Mechanism of Action

Delamin is a pharmacologic agent designed to modulate receptor- and enzyme-mediated signaling within specific biological systems. Its mechanism focuses on influencing the operational state of processes that exhibit heightened or dysregulated activity.


Modulation of Receptor-Mediated Signaling

This domain covers Delamin's primary action: engaging mechanisms that either initiate or suppress signaling sequences via cell surface receptors. By modifying these early molecular steps, the drug influences systems where specific transmitters or mediators dominate, ultimately altering the magnitude of downstream physiological response.


Adjustment of Enzymatic Cascades

Delamin is also relevant in systems where targeted pathway adjustment is required by affecting key enzymes. The drug modifies intermediate steps within enzymatic cascades, particularly those that drive enhanced physiological responses, which reduces the concentration or functional activity of specific mediators and leads to a change in pathway kinetics.

Dosage and Administration Information

How Delamin is Used: Administration Guidelines

Delamin (Dexchlorpheniramine Maleate) is intended for oral administration across all its available forms, including syrup, immediate-release tablets, and extended-release preparations. The medication may be taken with or without food.

Dosage and Frequency

The standard dosing regimen is differentiated by patient age and the formulation used. The immediate-release form is typically administered every 4 to 6 hours as needed. For adults and children 12 years and older, the usual dose is 2 mg. This frequent schedule requires adherence to a maximum daily dose that should not exceed 8 mg of the active ingredient in a 24-hour period.

Extended-release preparations, which typically contain 4 mg or 6 mg, are administered less frequently, often on a once-daily schedule or every 8 to 10 hours. The drug is intended for short-term use until symptomatic relief is no longer required.

Population-Specific and Handling Rules

Specific rules govern administration for certain groups and formulations. Older adults (age 60 years and older) typically utilize the lowest effective dose or a less frequent dosing schedule due to potentially altered clearance rates. The extended-release forms are not approved for use in children younger than six years of age.

Proper administration protocols must be followed to maintain the integrity of the dose. Extended-release tablets or capsules must be swallowed whole and must not be crushed, chewed, or broken.

When using the syrup, an accurate dose-measuring device must be used for dispensing, as household utensils can lead to inaccuracies.

Recent Clinical Evidence

Delamin: Recent Clinical Evidence


Clinical development for Delamin (delamanid) has primarily focused on its use within an optimized background regimen (OBR) for treating multidrug-resistant tuberculosis (MDR-TB). The primary measure of effect in early studies was sputum culture conversion (SCC), a laboratory marker indicating the absence of viable Mycobacterium tuberculosis in sputum samples.

Key Trial Findings

A pivotal Phase 2, randomized, placebo-controlled trial (Trial 204) evaluated the addition of Delamin to an OBR over a two-month period. Findings from this trial indicated that a statistically higher proportion of patients receiving Delamin plus OBR achieved SCC by Day 57 compared to those receiving placebo plus OBR. This difference was observed for both the 100 mg twice-daily and 200 mg twice-daily dose groups.

Long-term follow-up and pooled analyses from several trials suggest that a longer duration of Delamin treatment (six months or more) may be associated with more favorable treatment outcomes, including confirmed microbiological cure or treatment completion, when compared to short-term use (two months or less).

Safety Profile Observations

The most frequently reported adverse event observed in clinical trials that occurred at a higher rate in the Delamin treatment arms compared to the placebo group was QT interval prolongation on an electrocardiogram (ECG). This finding is a key consideration when Delamin is used, particularly in patients with pre-existing cardiac conditions or those receiving other medications known to affect the heart's electrical activity. Other commonly reported events, generally mild to moderate, included gastrointestinal issues such as nausea, vomiting, and dizziness. Post-authorization surveillance studies have supported the established safety profile, noting that QT interval prolongations were generally manageable.

Key Studies & References WHO consolidated guidelines on drug-resistant tuberculosis treatment

Frequently Asked Questions (FAQ)

Common questions about Delamin (FAQ)


Q: Why is Delamin sometimes referred to by a different name?

Delamin is a specific trade name for the medication. The active ingredient in the drug is Dexchlorpheniramine Maleate, which is the name often used in official prescribing information or by pharmacists. This distinction between the brand name and the active ingredient is common for prescription medications.


Q: How is Delamin generally different from other similar treatments in its class?

Delamin is classified as a first-generation antihistamine. Official documents describe the drug as the more potent S-enantiomer of the older compound, chlorpheniramine. This structural difference accounts for the specific general properties and effects associated with Delamin compared to other agents in its class.


Q: How common are side effects with Delamin?

Regulatory documents list specific effects as 'commonly documented,' such as drowsiness, dizziness, and dry mouth. While official sources confirm these effects are expected to occur frequently, they do not generally provide specific frequency percentages for patients.


Q: Does Delamin have a known impact on driving or operating machinery?

Official labeling notes that engaging in hazardous tasks that require complete mental alertness, such as driving or operating heavy machinery, should be avoided until the drug's effects are known. This precaution is advised until the individual understands how the drug's effects manifest in them.


Q: What is the usual general procedure if a dose of Delamin is missed?

If the medication is taken regularly and a dose is forgotten, regulatory guidance describes that the missed dose is generally taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidance often indicates that the missed dose should be skipped and the regular schedule continued.


Q: Can Delamin be taken alongside common over-the-counter pain relievers?

The drug's interaction profile focuses on additive effects with central nervous system (CNS) depressants. Official warnings state that a healthcare provider should be informed about all over-the-counter (OTC) medicines that are being taken before Delamin is used. This precaution helps address the risk of additive CNS effects or other potential overlaps.


Q: What is generally known about taking Delamin during pregnancy or while breastfeeding?

Taking the drug while breastfeeding is contraindicated (advised against) in official labeling. For use during pregnancy, official information indicates that professional assessment is required, as it is not known if the drug could affect an unborn baby.


Q: What are the general expectations about the drug’s effectiveness once it is working?

Studies and official product information indicate that Delamin is intended to provide symptomatic relief for allergic conditions. This action helps reduce the physiological reactions that lead to classic symptoms such as sneezing, itching, and a runny nose.


Q: Where can a patient find the official FDA or EMA prescribing information for Delamin?

Official prescribing information can be found on government-sponsored websites. Examples include the FDA's Drugs@FDA service, the NIH's DailyMed service, or the websites of other regulatory bodies like the European Medicines Agency (EMA).


Q: Is Delamin available over the counter or only by prescription?

Delamin, when sold as a single-ingredient product, is typically available by prescription only. However, its active ingredient is sometimes included in over-the-counter combination medications intended for the temporary relief of cold and allergy symptoms.


Q: Are there any long-term safety risks associated with taking Delamin?

First-generation antihistamines like Delamin are generally intended for short-term use, as indicated in regulatory guidelines. Warnings address the potential for side effects with prolonged use, such as the development of tolerance or the potential for certain long-term anticholinergic effects.


Q: Does Delamin typically cause changes in appetite or weight?

Official adverse event reports list loss of appetite as a possible side effect. Additionally, certain studies have noted that some drugs in the first-generation antihistamine class may have a potential association with increased appetite and weight changes.


Q: Can Delamin affect mood or cause feelings of anxiety?

Official adverse event reporting lists central nervous system (CNS) effects that are classified as paradoxical reactions. These include symptoms such as nervousness, excitement, and irritability. Official information on this class of drug emphasizes the importance of informing a healthcare provider if such reactions occur.


Q: Are there any specific signs that a potential side effect requires medical attention?

Official patient counseling information describes conditions where use should be stopped and immediate medical attention is necessary if severe symptoms occur. Examples of these severe symptoms include signs of an allergic reaction, extreme confusion, or difficulty with urination.


Q: What should be done if an allergic reaction is suspected while taking Delamin?

Official guidance indicates that if symptoms of an allergic reaction are suspected, such as hives, difficulty breathing, or swelling of the face, lips, or throat, the drug should be immediately discontinued. Under these conditions, emergency medical attention is necessary.


Q: How long does it typically take for Delamin to start working or for effects to be noticeable?

According to official product monographs, the antihistamine effect of the immediate-release formulation is typically reported to be apparent within one to three hours following oral administration. The onset of effects may vary based on the individual and the specific formulation used.


Q: Is it generally recommended to take Delamin in the morning or at night?

The drug is typically taken every 4 to 6 hours as needed, according to dosage guidelines. Due to the common side effect of drowsiness, the timing of administration is often adjusted to minimize daytime sedation.


Q: Does Delamin need to be taken at the exact same time every day for consistency?

Since the drug is often taken 'as needed' for symptoms, precise time consistency is not always a universal requirement. If a healthcare provider prescribes it for regular maintenance, a consistent schedule is used to maintain steady drug levels in the body.


Q: If I am taking other medications, how can I find information on potential interactions with Delamin?

Official patient counseling information states that a healthcare provider should be informed about all medications being taken. This includes prescription, over-the-counter (OTC) medicines, and supplements, which allows the provider to determine if the drug is right for them.


Q: Does Delamin interact with common supplements like vitamins or herbal remedies?

Official warnings state that a healthcare provider should be informed about all herbal products, vitamins, and other supplements being taken before Delamin is used. This is necessary because some of these substances may have minor interactions or contribute to existing side effects.


Q: Are there any known interactions between Delamin and caffeine intake?

Official labeling for some products containing the active ingredient indicates that caution should be exercised regarding caffeine intake. This is due to the potential for excessive caffeine to increase certain central nervous system side effects like nervousness or excitability.


Q: Is Delamin ever used or studied for use in children or adolescents?

Yes, official dosing information is available for children as young as 2 years old for the liquid/syrup form and 6 years old for certain tablet forms. This confirms that the drug is used in these age groups under the supervision of a healthcare professional.


Q: Are there any known restrictions on using Delamin for people with high blood pressure?

Official labeling for products containing the active ingredient indicates that high blood pressure is a condition about which a healthcare provider should be consulted before the drug is used. This is a common precaution for this class of medication.

How should Delamin be stored and disposed of?

The official storage of Delamin (Dexchlorpheniramine Maleate) requires strict adherence to documented temperature, protection, and security parameters.

Storage and Handling Requirements

Condition Official Regulatory Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). Short excursions are permitted up to 30 C (86 F).
Protection Protect from excessive heat, moisture, and light. The oral solution must not be frozen.
Container Rule Keep in the original container, tightly closed. The liquid form requires a light-resistant container and child-resistant closure.
Child Safety Must be stored out of the sight and reach of children.

Official Disposal Rules

Expired or unused Delamin must be disposed of according to local, state, and federal regulations, often utilizing community drug take-back programs. The product must not be allowed to enter water courses or sewage systems to prevent environmental contamination. If a take-back option is unavailable, non-flushable medicines should be mixed with an undesirable substance, sealed in a container, and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Delamin found in:

A-Z Index: